NEW YORK (GenomeWeb) – OpGen has raised about $1.1 million toward a targeted $1.5 million financing round, the firm disclosed in a regulatory document recently.

A spokesperson for the Gaithersburg, Md.-based microbial genetics analysis firm said that the initial funds are part of a Series B financing round that OpGen expects to close in the fall. It will use the money to commercialize the Acuitas MDRO Gene Test, a molecular test for identifying patients at risk of harboring antibiotic-resistant disease-causing microbes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.